The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund confirmed on Wednesday its agreement with Dr. Reddy Laboratories Private Limited, a global pharmaceutical company headquartered in India, about their cooperation on clinical trials and work on the distribution of the Sputnik V vaccine in India.
“Sputnik V Vaccine is undergoing a trial for the coronavirus Pandemic, is based on a well- prepared adenoviral vector platform maintaining all the necessary safety measures,”, a statement from the fund.
It is said, the deliveries of these could begin in late 2020 after all the clinical trials are successfully done along with the registration of vaccines by the regulatory authorities in India. This agreement shows the seriousness of the countries and organizations towards having a clear insight to have a diversified anti-COVID vaccine to protect their populations.
#RDIF and @drreddys, a global pharmaceutical company headquartered out of India, have agreed to cooperate on clinical trials and distribution of @sputnikvaccine in #India. RDIF shall supply to Dr. Reddy’s 100 million doses of the vaccine. More: https://t.co/NLqJBFP27S pic.twitter.com/ZLs9IWIedr
— RDIF (@rdif_press) September 16, 2020
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, made an optimistic remark by saying, “We are very pleased to partner with Dr.Reddy’s in India. Dr. Reddy’s has had a very well established and respected presence in Russia for over 25 years and is one of the leading pharmaceutical companies in India. India is amongst most severely impacted countries from COVID 19 and we believe our human adenovirus dual vector platform will provide a safe and scientifically validated option to India in the battle against COVID 19”
YOU MAY LIKE TO READ: Covid-19: Russian Vaccine Shows Signs Of Antibody Response, Says Lancet Study
Providing us a ray hope, Co-Chairman and Managing Director of Dr. Reddy’s Laboratories G V Prasad stated, “We are pleased to partner with RDIF to bring the vaccine to India. The Phase I and II results have shown promise, and we will be conducting Phase-I ll trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India”
#DrReddysNews: Russian Direct Investment Fund (RDIF) and Dr. Reddy’s to cooperate on clinical trials and supply of 100 million doses of Sputnik V vaccine to India. Read more here: https://t.co/BTaSkkcuri pic.twitter.com/8WeMyJGUsT
— Dr. Reddy’s (@drreddys) September 16, 2020
The ICMR Director General Balram Bhargava also believes Russia has a good history of manufacturing vaccines. India and Russia are working their mechanism, and therefore it is an optimistic approach.
While a week back the member of NITI Aayog, Dr. V.K. Paul said, “The vaccine developed by Russia has been under consideration of the country. The government of Russia approached our government & sought help on two basic things- to consider its manufacturing through our network of companies, and phase 3 studies in India”
The vaccine developed by Russia has been under consideration of the country. Government of Russia approached our govt & sought help on two counts- to consider its manufacturing through our network of companies, and phase 3 studies in India: Dr VK Paul, Member (Health), NITI Aayog pic.twitter.com/d8f9A40k85
— ANI (@ANI) September 8, 2020
Kirill Dmitriev continued by saying, “RDIF partners will receive an effective and safe drug to fight the coronavirus. The platform of human adenoviral vectors, which is the core of the Russian vaccine, has been tested in more than 250 clinical studies over decades, and it has been found safe with no potential negative long-term consequences.”